Myelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute myeloid leukemia. With hematopoietic stem cell transplantation representing the only curative option for patients with MDS, the field has not seen the rapid evolution in treatments witnessed in other hematological malignancies.

In this podcast, Amer Zeidan, MBBS, Yale University, and Yale Cancer Center, New Haven, CT, chairs a discussion evaluating issues pertaining to MDS, from clinical trial designs to the latest understanding of disease biology as well as future outlooks. Dr Zeidan is joined by Amy DeZern, MD, MHS, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Michael Savona, MD, of Vanderbilt University Medical Center, Nashville, TN, Mikkael Sekeres, MD, MS, of The Cleveland Clinic, Cleveland, OH, and David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA.